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24Objectives: The aim of this study was to identify
associations between the smoothness index of central SBP
(CSBP) and changes of ambulatory carotid femoral pulse
wave velocity in response to 20-week treatments with
losartan and amlodipine vs. losartan and
hydrochlorthiazide combinations.
Methods: For 142 (losartan and hydrochlorthiazide: 72,
losartan and hydrochlorthiazide: 70) patients examined
with ambulatory central blood pressure (BP) monitoring
device, we calculated smoothness indices and trough-to-
peak ratios of brachial SBP, CSBP, ambulatory pulse
pressure amplification (APPA), ambulatory augmentation
index at heart rate 75 beats per minute (AAIx75) and
ambulatory carotid femoral pulse wave velocity (AcfPWV).
Results: Mean age was 58.912.3 years, and women
accounted for 25.9%. Changes in office SBP/DBP were not
different between groups (losartan and hydrochlorthiazide:
15.215.0/7.88.0 vs. losartan and amlodipine:
14.913.7/9.27.5mmHg). Reduction of 24-h CSBP
was not significantly different (losartan and
hydrochlorthiazide: 6.4 1.1 vs. losartan and amlodipine:
9.21.1mmHg, P¼ 0.074). Reduction in nocturnal AcfPWV
was greater in the losartan and amlodipine group (losartan
and hydrochlorthiazide: 0.090.05 vs. losartan and
amlodipine: 0.260.05m/s, P¼0.0216). Intraindividual SIs
for CSBP were higher in the losartan and amlodipine group
(0.400.57 vs. 0.650.74, P¼0.022). In multivariable
regression analysis, smoothness index of CSBP was
independently associated with the losartan and amlodipine
group. In model additionally considering the changes in
arterial stiffness, decrease in AcfPWV instead of the
treatment group was independently associated with
smoothness indices. In mediation analysis, smoothness index
was fully mediated by reduction in night-time AcfPWV.
Conclusion: Losartan and amlodipine combination was
superior to the losartan and hydrochlorthiazideDO
90 www.jhypertension.comcombination in terms of achieving higher smoothness
index for CSBP after 20-week treatments. The effect of
losartan and amlodipine on smoothness index was fully
mediated by reduction of night-time AcfPWV.
Keywords: ambulatory, amlodipine, aortic pressure,
arterial stiffness, blood pressure monitoring, central blood
pressure, combination drug therapy, hypertension,
losartan, smoothness index, thiazides, trough-peak ratioI:10.1097/HJH.0000000000002202
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Smoothness index and ambulatory central BPAbbreviations: AAIx, ambulatory augmentation index;
AAIx75, augmentation index at heart rate 75 beats per
minute; ABPM, ambulatory blood pressure monitoring;
AcfPWV, ambulatory carotid femoral pulse wave velocity;
ACR, albumin creatinine ratio; AHM, antihypertensive
medication; AIx, augmentation index; APPA, ambulatory
pulse pressure amplification; BP, blood pressure; CCB,
calcium channel blocker; cfPWV, carotid femoral pulse
wave velocity; CSBP, central SBP; HCTZ,
hydrochlorthiazide; PPA, pulse pressure amplification; RAS,
renin–angiotensin systemINTRODUCTIONH
ypertension is the key risk factor for cardiovascular
death, the leading cause of death worldwide [1].
Control of blood pressure (BP) using antihyperten-
sive medications (AHMs) has been proven to prevent hyper-
tension-related cardiovascular complications [1]. In most
hypertension patients, combination therapy is frequently
needed as a stepwise escalation or as the first regimen,
except in the fragile elderly or when SBP is less than
150mmHg [2]. The preference for the combination including
specific class of AHM is documented in regional hyperten-
sion guidelines [3]. Nevertheless, the rationale behind the
preference is usually beyond the scope of BP measurement,
as shown in some outcome trials; clinical outcomes for the
preferred combination appeared to be better than the expec-
tation conceived by BP difference [4,5].
With respect to the efficacy of BP reduction by AHM,
central BP was suggested to be more important for clinical
outcome. For example, compared with brachial BP, central
BP showed better correlation with target organ damage and
BP-lowering efficacy [6]. In the BP GUIDE study, it was
demonstrated that central BP-guided practice could make
the practice be more cost-effective [7].
Renin-angiotensin system (RAS) inhibitors are preferred
for combination therapy with calcium antagonist or with
diuretics. However, there is a preference for calcium chan-
nel blocker (CCB) over diuretics for combination therapy
because of the superiorities of the BP-lowering efficacy and
clinical outcome [8]. In addition to pharmacologic profiles,
patient characteristics such as salt sensitivity, volume status,
age, obesity, vascular stiffness and racial background
appeared to be associated with efficacy [9]. As shown in
the J-CORE study, superiority of CCB to hydrochlorothia-
zide on top of olmesartan-based treatment could be dem-
onstrated only using aortic pulse wave velocity.
In terms of the limitations of use of clinical BP measure-
ment, diurnal BP variability may be differently affected by
drug class or some combination regimens [10]. For exam-
ple, 24-h BP control or action duration of AHM represented
by parameters such as smoothness index or trough–peak
ratio may be different among some combination regimens
[11]. Nevertheless, there are few studies comparing the
efficacy of smoothness index and trough–peak ratio of
combination therapy using RAS inhibitor and CCB vs.
RAS inhibitor and diuretics.
TheMobil-O-Graph PWAABPMdevice, with themultiple
measurement during 24-h ambulatory monitoring, providesJournal of Hypertensionboth brachial and central BP using the ARC Solver algorithm
[12]. The generalized transfer function was assumed to be
comparable to the individualized transfer function in resting
status [13]. Currently usedvascular parameters suchas central
BP and pulse pressure amplification (PPA), carotid femoral
pulse wave velocity (cfPWV), augmentation index (AIx) are
recommended to be measured in the fully resting state for
hypertensive patients; however, the clinical value of central
BP and other vascular parameters measured in the ambula-
tory state are unknown [14,15]. Moreover, whether the
concept of smoothness index could be applied to those
parameters is also unknown.
Recently, we reported that ambulatory central SBP
(CSBP) was significantly more reduced by losartan and
amlodipine than by losartan and hydrochlorothiazide after
20-week treatment, despite the fact that BP reduction was
not significantly different [16].
Therefore, as a substudy, we analysed the association
between SI of brachial or central BPs and ambulatory param-
eters of arterial stiffness in response to 20-week treatmentwith
losartan and amlodipine vs. losartan andhydrochlorothiazide.
MATERIALS ANDMETHODS
Study design
The original trial had a multicentre, double-blinded, active
controlled, randomized design to compare the efficacy of a
fixed-dose combination of losartan and amlodipine with
that of losartan and hydrochlorothiazide after 20 weeks of
treatment [17]. Clinical BP was the primary endpoint. Sec-
ondary endpoints were central BP and other vascular
haemodynamic parameters such as ambulatory cfPWV
(AcfPWV), AIx (AAIx) and ambulatory PPA (APPA). Micro-
albuminuria was expressed as albumin creatinine ratio
(ACR) was also included.
Briefly, the studywas performed as follows. After screen-
ing, eligible patients went through an open-labelled run-in
period with losartan 50mg daily for 4 weeks. Then, only
patients with clinic SBP at least 140mmHg were random-
ized into blinded treatment assignments, either losartan/
amlodipine 50/5mg daily or losartan/dihydrochlorothia-
zide 50/12.5mg daily with a placebo drug of the other
group. After 4-week treatment, uptitration was performed
by increasing the dose to losartan/amlodipine 100/5mg
daily or losartan/dihydrochlorothiazide 100/25mg daily
when clinic SBP remained at least 140mmHg.
Study population
Among 220 participants, 45 individuals refused follow-up
ambulatory BP monitoring (ABPM); therefore, 185 individ-
ual data were analysed. Finally, 143 individual data were
acquired for the final analyses with exclusion criteria (avail-
able data points less than 80% after applying popular
editing criteria) [18].
Ambulatory monitoring of blood pressures,
pulse pressure amplification, augmentation
index and ambulatory carotid femoral pulse
wave velocity
Clinical BP was obtained in the sitting position with the
pressure cuff placed at either the right or left brachial area,www.jhypertension.com 2491
Shin et al.using a semi-automated sphygmomanometer (HEM-7080IC;
Omron Healthcare Co, Kyoto, Japan). After 5min of rest, BP
wasmeasured three timeswith an intervalof 2min, andmean
pressure was used for analysis. Measurements of BPs, AAIx,
APPA and AcfPWV were performed for 24h with 30-min
intervals using the previously validated, automated oscillo-
metric device (Mobil-O-graph 24h PWA monitor; IEM
Gmbh, Stolberg, Germany) [12]. Daytime and night-time
were defined by narrow fixed interval method. BPs during
the period between 0800 and 2100 h were regarded as
daytime BP and BPs during the period between midnight
and 0500 hwas regarded as night-time BP. Twenty-four hour
BP was calculated by daytime BP x [1–(sleep duration in
hour/24)] þ night-time BP x (sleep duration in hour/24).
Nocturnal dipping was defined as night-time brachial SBP
divided by daytime brachial SBP x 100 (%).
All patients took the study drug at the time of starting the
ambulatory monitoring. PPA was defined as the ratio of
brachial SBP to CSBP [19]. AAIx75 was calculated by cali-
brating the AAIx at the heart rate of 75 beats per minute.
The smoothness index was calculated using hourly
changes of the study parameters from baseline to 20-week
treatment. Smoothness index was defined as average of
hourly changes divided by standard deviation of those
hourly changes during a 24-h time period. All hourly data
for each hour interval from the time when monitoring
started and the study drug was taken were averaged to
generate a single hourly change [18]. Intraindividual
smoothness index was calculated by using hourly changes
for each individual to test statistical comparison between
groups [20].
Trough–peak ratio
Global trough–peak ratio was calculated using BP reduc-
tion in the trough period, defined as average BP over 22–
24 h from drug intake, divided by peak BP reduction,
defined as average BP reduction of peak reduction from
second to eighth hours from drug intake and adjacent BPs.
Intraindividual trough–peak ratio was calculated with 2-h
average windows; the corresponding number of trough–
peak ratio readings according to the groups were statisti-
cally compared [21,22].
Ethics
Patients were recruited from 20 medical centres nationwide
in Korea. The study was approved by each institutional
review board. Written consent was obtained for all
study patients.
Statistical analysis
Data were expressed as mean standard deviation for
normal distribution and median with 95% confidence inter-
val (95% CI) for nonnormal distribution. Baseline character-
istics were compared using the Student’s t-test for
continuous variables and the chi-square or Fisher’s exact
test for categorical variables.
Because the present study is a substudy for the random-
ized study, the baseline characteristics may differ for some
variables. Efficacies according to treatment groups were
compared using adjusted means and standard errors for2492 www.jhypertension.combaseline data using a generalized linear model. For the
statistical testing for the difference in the reduction of
AAIx75 and AcfPWV during treatment were adjusted for
clinic brachial SBP at baseline and at week 20 because of the
SBP dependencies.
For intergroup comparison of smoothness index, the
intraindividual smoothness indices were compared using
two-sample t-tests. For intergroup differences of nonnor-
mally distributed trough–peak ratios, point estimates and
95% Cls of the net treatment difference between LH vs. LA
groups were computed according to the method of calcu-
lating CI for nonparametric analyses [23,24]. For intraindi-
vidual trough–peak ratios, the Kruskal–Wallis
nonparametric test was performed.
To examine the associated factors for smoothness indices
of brachial SBP and CSBP, stepwise multivariate regression
analysis was performed and the entry was decided by the P
value less than 0.1 and the stay was decided by the P value
less than 0.05. Model 1 includes independent variables such
as baseline age, sex, smoking or drinking status, height and
waist circumference, and treatment group.Model 2 addition-
ally includes clinic brachial SBP at baseline and week 20,
changes in ACR, fasting blood glucose, uric acid, mean
ambulatory heart rate, mean APPA, mean AAIx75, mean
AcfPWV, daytime AcfPWV and night-time AcfPWV. For
significant factors associated with both smoothness index
and treatment group, mediation analysis was performed
using the ‘process’ macro using mediation model 4 [25].
Covariates adjusted for mediation analysis were identical
to independent variables inmodel 1 except treatment group.
The statistical software package used was SAS (version 9.4,
SAS Institute Inc., Cary, North Carolina, USA). P values less
than 0.05 were regarded as statistically significant.RESULTS
Baseline characteristics
Mean age was 58.9 12.3 years and women accounted for
25.9%. Prevalence of drinking and current smoking were
51.5 and 21.7%, respectively. Mean BMI was 25.9 2.9 kg/
m2 and diabetesmellitus was noted in 14.7%. Clinic SBP and
DBP were 153.8 10.2 and 92.4 8.5mmHg, respectively.
Prevalence of women was marginally higher in the losartan
and hydrochlorthiazide group and uric acid levels were
significantly higher in the losartan and amlodipine group
(Table 1). Baseline BPs were not different, but nocturnal
brachial SBP was marginally higher and nocturnal CSBP
was significantly higher in the losartan and amlodipine
group than in the losartan and hydrochlorthiazide group.
Nocturnal dipping was more prominent in the losartan and
hydrochlorthiazide group than in the losartan and amlodi-
pine group. APPA, AAIx75 and AcfPWV were similar
between groups.
Changes at 20 weeks
Reductions in clinic BPs were not different between groups.
However, ambulatory brachial SBP decreased more signifi-
cantly in the losartan and amlodipine group than in the
losartan and hydrochlorthiazide group during the 24-h
period and during daytime. Reduction of nocturnal CSBPVolume 37  Number 12  December 2019
TABLE 2. Comparison between losartan and hydrochlorothiazide
vs. losartan and amlodipine groups in the reduction of
the study parameters at week 20
Losartan
and
HCTZ
(n¼72)
Losartan
and
amlodipine
(n¼70) Pa
Clinic SBP (mmHg) 15.215.0 14.913.7 0.9003
Clinic DBP (mmHg) 7.88.0 9.27.5 0.2833
Brachial SBP, 24 h (mmHg) 6.51.2 9.91.2 0.0449
Brachial SBP, daytime (mmHg) 7.01.3 10.81.3 0.0429
Brachial SBP, night-time (mmHg) 5.51.3 8.41.3 0.1264
Central SBP, 24 h (mmHg) 6.41.1 9.21.1 0.0738
Central SBP, daytime (mmHg) 6.81.2 9.61.1 0.0836
Central SBP, night-time (mmHg) 4.91.3 8.31.3 0.0613
Ambulatory AIx75, 24-h (%) 0.40.6 1.10.6 0.0955
Ambulatory AIx75, daytime (%) 0.10.7 1.60.7 0.1296
Ambulatory AIx75, night-time (%) 1.21.0 0.41.0 0.2705
Ambulatory cfPWV, 24-h (m/s) 0.150.05 0.270.05 0.0507
Ambulatory cfPWV, daytime (m/s) 0.160.05 0.280.05 0.0808
Ambulatory cfPWV, night-time (m/s) 0.090.05 0.260.05 0.0235
Albumin creatinine ratio (mg/g) 8.272.43 10.562.45 0.5100
Fasting blood glucose (mg/dl) 7.041.99 2.631.97 0.1487
Uric acid (mg/dl) 0.380.11 0.190.11 0.0002
AIx75, augmentation index calibrated for the assumed ambulatory heart rate of 75 beats
per minute; cfPWV, carotid femoral pulse wave velocity; HCTZ, dihydrochlorothiazide.
aAdjusted for baseline difference and additionally adjusted for SBPs at baseline and at
week 20 in case of AIx and cfPWV. Mean standard error.
TABLE 1. Baseline characteristics of losartan and hydrochlorothiazide
group vs. losartan and amlodipine group
Losartan
and
HCTZ
(n¼72)
Losartan
and
amlodipine
(n¼70) P
Age (years) 59.311.7 58.412.9 0.6633
Female (%) 36.9% 22.9% 0.0655
BMI (kg/m2) 25.93.0 25.92.9 0.9758
Drinking 56.2% 45.7% 0.2142
Smoking 24.6% 18.5% 0.3808
Waist circumference (cm) 89.99.0 89.58.5 0.7849
Clinic SBP (mmHg) 153.79.5 153.911.0 0.5713
Clinic DBP (mmHg) 92.58.4 92.98.8 0.8778
Heart rate (bpm) 71.210.5 69.49.6 0.2530
Fasting blood glucose (mg/dl) 109.717.0 105.418.3 0.1576
Creatinine (mg/dl) 0.90.2 0.90.2 0.1482
Uric acid (mg/dl) 5.41.3 5.81.2 0.0349
Total cholesterol (mg/dl) 187.238.6 182.136.5 0.4123
Haemoglobin A1c (%) 5.80.7 5.80.7 0.581
Sodium (mEq/l) 141.02.2 140.82.0 0.5204
Potassium (mEq/l) 4.40.3 4.40.3 0.4793
Albumin creatinine ratio (mg/g) 33.391.3 24.947.0 0.4986
Brachial SBP, 24h (mmHg) 135.710.4 137.213.0 0.4619
Brachial SBP, daytime (mmHg) 141.011.0 141.213.9 0.9289
Brachial SBP, night-time (mmHg) 125.313.7 129.714.1 0.0631
Brachial DBP, 24 h (mmHg) 86.89.4 87.010.1 0.8943
Brachial DBP, daytime (mmHg) 91.29.7 90.210.3 0.5276
Brachial DBP, night-time (mmHg) 78.111.6 81.011.5 0.1355
Heart rate, 24 h (bpm) 71.69.7 68.88.5 0.0697
Heart rate, daytime (bpm) 75.710.8 72.58.9 0.0535
Heart rate, night-time (bpm) 63.89.2 62.19.8 0.2851
Nocturnal dipping (mmHg) 10.99.2 7.97.5 0.0364
Dipper (%) 58.9% 40.0% 0.0238
Central SBP, 24h (mmHg) 125.49.6 127.412.4 0.2790
Central SBP, daytime (mmHg) 129.910.1 130.413.5 0.7727
Central SBP, night-time (mmHg) 116.712.7 121.813.6 0.022
Ambulatory PPA, 24-h 1.270.08 1.250.06 0.1032
Ambulatory PPA, daytime 1.290.08 1.270.07 0.1088
Ambulatory PPA, night-time 1.230.11 1.220.11 0.6368
Ambulatory AIx75, 24-h (%) 23.99.5 22.39.4 0.3173
Ambulatory AIx75, daytime (%) 24.49.3 22.08.7 0.123
Ambulatory AIx75, night-time (%) 23.212.2 22.812.6 0.8457
Ambulatory cfPWV, 24-h (m/s) 8.81.6 9.01.8 0.7202
Ambulatory cfPWV, daytime (m/s) 9.01.6 9.11.8 0.8345
Ambulatory cfPWV, night-time (m/s) 8.51.7 8.71.8 0.5051
AIx75, augmentation index calibrated for the assumed ambulatory heart rate of 75 beats
per minute; cfPWV, carotid femoral pulse wave velocity; HCTZ, dihydrochlorothiazide;
PPA, pulse pressure amplification.
Smoothness index and ambulatory central BPunadjusted for baseline difference was significantly greater
in the losartan and amlodipine group than in the losartan
and hydrochlorthiazide group (4.1 12.2 vs.
9.4 12.2mmHg, P¼ 0.0106); however, when adjusted
for baseline level or regression to mean, it was not signifi-
cantly different, as summarized in Table 2. APPA changed
very little (less than 0.01). The changes in AcfPWV and
AAIx75-adjusted baseline difference and clinic SBPs were
not significantly different between groups except that the
reduction in nocturnal AcfPWV was greater in the losartan
and amlodipine group (losartan and hydrochlorthiazide:
0.09 0.05 vs. losartan and amlodipine: 0.26 0.05m/s,
P¼ 0.0235) even with adjustment for clinic brachial SBP
at baseline and at week 20 because of the SBP
dependencies.Journal of HypertensionDifference in smoothness index
As summarized in Table 3, intraindividual smoothness
indices in both brachial SBP and CSBP in losartan and
amlodipine group were higher than those in the losartan
and hydrochlorthiazide group. This was attributable both to
greater hourly reduction in mean BPs and less variability in
hourly BP reduction.
Trough–peak ratio
The individual trough–peak ratios for brachial SBP and
CSBP were higher in the losartan and amlodipine group
than in the losartan and hydrochlorthiazide group, but the
difference was not statistically significant. The global
trough–peak ratio of brachial SBP and CSBP were higher
in the losartan and amlodipine group than in the losartan
and hydrochlorthiazide group as shown in Fig. 1 (Table 4).Factors related to smoothness index of brachial
SBP and central SBP
As summarized in Table 5, in multivariable regression analy-
sismodel 1 to explore the factors related to smoothness index
of brachial SBP and CSBP, treatment group and age were
independent factors associated with smoothness index in
brachial SBPand the effect of treatment regimenwas theonly
factor associatedwith smoothness index in CSBP. Inmodel 2
for smoothness index of brachial SBP, improvement of
AcfPWV was the only independently associated factor. In
model 2 for smoothness index of CSBP, the improvement of
AcfPWV and increase in APPA were independently associ-
ated factors (Table 5). In mediation analysis for reduction in
night-time AcfPWV, which was the only covariate showing
statistically significant correlations with both treatment
groups and smoothness index of CSBP, the total effectwww.jhypertension.com 2493
TABLE 3. Comparison between losartan and hydrochlorothiazide
vs. losartan and amlodipine group in intraindividual
smoothness index of brachial and central SBP and
vascular parameters
Losartan
and
HCTZ
(n¼72)
Losartan
and
amlodipine
(n¼70) P
Smoothness index for brachial SBP 0.390.57 0.660.78 0.0151
Mean hourly reduction (mmHg) 6.3310.02 10.412.5 0.0311
SD of hourly reduction (mmHg) 20.26.7 17.05.2 0.002
Smoothness index for central SBP 0.400.57 0.650.74 0.022
Mean hourly reduction (mmHg) 6.159.03 9.7911.45 0.0362
SD of hourly reduction (mmHg) 18.595.67 16.04.8 0.0036
AIx, augmentation index; cfPWV, carotid femoral pulse wave velocity; HCTZ,
dihydrochlorothiazide; PPA, pulse pressure amplification; SD, standard deviation.
Shin et al.between treatment group and smoothness index of CSBP
was fully mediated by reduction in night-time AcfPWV,
showing a significant indirect effect. Therefore, the direct
effect became no longer significant considering the media-
tion or indirect effect, which was completely attributable to
the reduction in night-time AcfPWV (Fig. 2, supplementary
Table, http://links.lww.com/HJH/B130).
DISCUSSION
The main finding of the present study was that, compared
with the losartan and hydrochlorthiazide group, the los-
artan and amlodipine group was independently associated
with intraindividual smoothness indices of brachial SBP and100
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2494 www.jhypertension.comCSBP, even though the reduction of 24-h CSBP was not
different between groups. The finding that reduction in
CSBP was not significantly different between groups con-
tradicted to findings of the original study can be explained
by the limited sample size because of exclusion of more
patients to calculate smoothness indices.
In contrast to the trough–peak ratio, which failed to
show a difference between the groups, intraindividual
smoothness indices successfully showed differences
between losartan and amlodipine and losartan and hydro-
chlorthiazide combinations. These findings appeared to be
consistent with the previous report suggesting the superi-
ority of smoothness index to trough–peak ratio in assessing
the 24-h BP-lowering effect of AHM [20]. In our study,
global trough–peak ratio was so high to be about 1 in
losartan and amlodipine combination group as shown in
Fig. 1. This unusually high value can be attributable to the
relatively weak peak effect of losartan and amlodipine
regimen, which could be attributable to occupational stress
which could blunt the effect of losartan and amlodipine
combination [26,27]. The fact that such an apparent differ-
ence does not mean statistical difference might be the
limitation of trough–peak ratio as the parameter indicating
24-h BP control efficacy of AHM. Taken together, smooth-
ness index seems to be better to reflect the 24-h BP-lower-
ing efficacy of AHM in the study population who are
actively engaged with physical or social activities.
Smoothness indices were first reported to be indepen-
dently associated with the improvement of AcfPWV in our
study. These findings are in line with those of previous
studies showing the correlation between smoothness index100
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TABLE 4. Comparison between losartan and hydrochlorothiazide vs. losartan and amlodipine group in intraindividual and global trough-
peak ratio of brachial and central SBPs
Intraindividual TP ratio
Group Median Difference P
Brachial SBP
Losartan and HCTZ (n¼72) 0.26 [0.68 to 0.80] 0.30 [0.07 to 1.30] 0.7202
Losartan and amlodipine (n¼70) 0.45 [0.45 to 1.08]
Central SBP
Losartan and HCTZ (n¼72) 0.34 [0.67 to 0.75] 0.24 [0.51 to 3.80] 0.0885
Losartan and amlodipine (n¼70) 0.48 [0.25 to 1.18]
Global TP ratio
Group Peak Trough TP ratio
Brachial SBP
Losartan and HCTZ (n¼72) 9.522.02 4.900.82 0.51
Losartan and amlodipine (n¼70) 11.831.18 12.160.24 1.03
Central SBP
Losartan and HCTZ (n¼72) 8.443.09 5.160.55 0.62
Losartan and amlodipine (n¼70) 11.711.79 12.700.66 1.08
[], 95% confidence interval; HCTZ, dihydrochlorothiazide; TP ratio, trough to peak ratio.
Smoothness index and ambulatory central BPwith changes in left ventricular mass or carotid intimamedia
thickness in terms of hypertension-mediated organ damage
[28,29]. By contrast to the finding in model 1 that the
treatment group was independently associated with
smoothness indices, according to the model 2, including
parameters for arterial stiffness, it could be suggested that
individual reduction of AcfPWV was more important than
the treatment regimen itself. Further study with larger
sample size is needed to demonstrate the association of
treatment regimen independently of the reduction
in AcfPWV.
In our original study, the losartan and amlodipine group
showed a higher reduction in 24-h AcfPWV than the los-
artan and hydrochlorthiazide group [16]. In the present
study, the reduction in AcfPWV was significantly different
only during the night-time between groups. This appears to
be attributable to reduced sample size for calculating theTABLE 5. Multivariable regression model for the factors associated
with smoothness index
Variable Beta Model Rsq Pa
Model 1
Smoothness index of brachial SBP
LA group (reference: LH group) 0.2698 0.0274 0.0148
Age 0.0097 0.0365 0.0327
Smoothness index of central SBP
LA group (reference: LH group) 0.2526 0.0363 0.0200
Model 2
Smoothness index of brachial SBP
Reduction of 24-h ambulatory cfPWV 1.5904 0.7878 <0.0001
Smoothness index of central SBP
Reduction of 24-h ambulatory cfPWV 1.5476 0.8253 <0.0001
Increase in mean pulse pressure
amplification
0.8510 0.8323 0.0243
Model 1 includes covariates of baseline age, sex, smoking or drinking status, height,
waist circumference and treatment group. Model 2 additionally includes clinic brachial
SBP at baseline and week 20, the changes in ACR, fasting blood glucose, uric acid,
mean ambulatory heart rate, mean APPA, mean AAIx75, mean AcfPWV, daytime
AcfPWV and night-time AcfPWV in addition to the model 1.
LA, losartan and amlodipine combination; LH, losartan and dihydrochlorothiazide
combination.
aStepwise multivariate regression analysis.
Journal of Hypertensionsmoothness index. However, it also suggests that the mea-
surement of cfPWV in the resting state may have more
differential value than the ambulatory nonresting state to
show the differences between treatment groups. Even
though CSBP and cfPWV are recommended to bemeasured
at resting status, our multivariable regression model 2
showed that reduction in 24-h AcfPWV instead of night-
time AcfPWV was independently associated with smooth-
ness indices. This finding suggests that further study to
define clinical usefulness of nonresting or AcfPWV
is needed.
Mediation analysis using the reduction in night-time
AcfPWV strongly suggested that the smoothness index
achieved by 20-week treatment by the two combination
regimens can be fully mediated by the reduction of night-
time AcfPWV (suppl. Table 1, http://links.lww.com/HJH/
B130).
Therefore, during antihypertensive therapy for an indi-
vidual patient, reduction of AcfPWV might be important to
predict smoothness index during AHM regardless of the
antihypertensive regimen. Whether this hypothesis can be
applied to resting change in cfPWV regarding the associa-
tion with smoothness index or clinical outcome needs
further study [30].
The difference between the ambulatory brachial SBP and
CSBP was about 10mmHg and the resultant mean APPA
appears to be consistent with findings of a previous study
done for single measurements [31]. However, the change in
APPAwas negligible with 20-week treatment, even with the
changes in BP and AcfPWV. Even though PPA has been
known to be important as a therapeutic response, there are
few studies of the therapeutic response of APPA [32].
The reduction of AAIxwas not different between groups
in the present study. Losartan and hydrochlorthiazide
combination was reported to be inferior to maximal los-
artan dosage uptitration in reducing AAIx [33]. Because
there was a tendency for more reduction in AAIx in the
losartan and amlodipine group than in the losartan and
hydrochlorthiazide group in which some increase in AAIxwww.jhypertension.com 2495
Losartan + 
amlodipine  
(reference: Losartan 
+ HCTZ) 
Smoothness index 
of central SBP 
Reducon of 
night-me
ambulatory cfPWV 
0.2656[0.1183]* 
0.1879[0.0726]* 1.1503[0.1027]* 
0.2161[0.0891] 
(indirect effect, P = 0.0117) 
0.0495[0.0862] 
(direct effect, p=0.5669) 
FIGURE 2 Path diagram showing full mediation of reduction of night-time carotid femoral pulse wave velocity regarding the relationship between different treatment
groups and smoothness index of central SBP. Data were expressed as estimate [standard error]. Adjusted covariates: baseline age, sex, brachial SBP, smoking or drinking
status, height and waist circumference. AcfPWV, ambulatory carotid femoral pulse wave velocity; HCTZ, dihydrochlorothiazide; SI, smoothness index. P<0.05; P for
indirect effect was calculated using Sobel test.
Shin et al.was noted, further study to compare losartan and amlodi-
pine combination vs. maximal losartan dosage would
be interesting.
Our study has some limitations. First, because it is a
substudy of a randomized clinical trial, selection bias may
be present and some of the baseline characteristics were
significantly different between groups. Even though the
changes of the study parameters were adjusted for baseline
difference, the study result could be biased. Second,
because of the smaller sample size, the marginal difference
in CSBP can be suggested as being significant by referring to
the original study result. Despite the marginal difference,
demonstration of the stronger association of CSBP and
AcfPWV than brachial SBP may be an interesting finding
in the present study.
In conclusion, 20-week treatment using losartan and
amlodipine combination is superior to losartan and dihy-
drochlorothiazide combination in achieving higher
smoothness indices of both brachial SBP and CSBP. Its
efficacy on higher smoothness index of CSBP was mediated
fully by reduction in night-time AcfPWV.
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